Dr Vidula and Dr Langer review the role of oral selective estrogen receptor degraders (SERDs) in the treatment of ER+/HER2- metastatic breast cancer and what patient populations would benefit the most from treatment with oral SERDs.
Dr Vidula and Dr Lu discuses how the improved progression-free survival seen with oral selective estrogen receptor degraders (SERDs) translates to clinical practice, and the most recent NCCN guidelines.